Английская Википедия:Avadel Pharmaceuticals

Материал из Онлайн справочника
Перейти к навигацииПерейти к поиску

Шаблон:Short description Шаблон:Use dmy dates Шаблон:Notability Шаблон:Infobox company

Avadel Pharmaceuticals plc Шаблон:NASDAQ, is a specialty pharmaceutical company. Avadel markets products in the hospital and primary care spaces. The Company is headquartered in Dublin, Ireland with operations in St. Louis, Missouri and Lyon, France.[1]

The company was founded as Flamel Technologies SA in Lyon, France in 1990.[2]

The company acquired Éclat Pharmaceuticals of St. Louis, Missouri in March 2012.[3][4]

On 8 February 2016, the company acquired FSC Holdings, LLC, which included its wholly owned subsidiaries FSC Pediatrics, Inc., FSC Therapeutics, LLC, and FSC Laboratories, Inc.[5]

On 3 January 2017, Flamel, Éclat, and FCS Pediatrics became Avadel Pharmaceuticals plc after the Company completed a cross-border merger from France to Ireland.[6]

In 2019, Mike Anderson, CEO of Avadel Pharmaceuticals has resigned, and Gregory Divis, COO of the company was appointed as his temporary successor. Meanwhile, Craig Stapleton, chairman of the Dublin-headquartered Avadel, has also stepped down. That same year, the company filed for Chapter 11 bankruptcy.[7][8]

In May 2023, Avadel Pharmaceuticals received FDA approval for Lumryz, an extended-release oral suspension of sodium oxybate.[9]

References

Шаблон:Reflist

External links

Шаблон:Authority control

Шаблон:Ireland-company-stub